Natural Product (NP) Details
General Information of the NP (ID: NP8210) | |||||
---|---|---|---|---|---|
Name |
Galangin
|
||||
Synonyms |
Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one; 548-83-4
Click to Show/Hide
|
||||
Species Origin | Plantago major ... | Click to Show/Hide | |||
Plantago major | |||||
Alpinia galanga | |||||
Disease | Brain cancer [ICD-11: 2A00] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H10O5
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
|
||||
InChI |
1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H
|
||||
InChIKey |
VCCRNZQBSJXYJD-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 548-83-4
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | A549/DDP cells were harvested, 5 * 106 cells were in jected subcutaneously into the right oxter of mice. | |||||
Experimental
Result(s) |
Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-KappaB and Bcl-2/Bax signaling pathways. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | ||
ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | |||
A-498 | CVCL_1056 | Renal cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells. | |||||
Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
KCL-22 | CVCL_2091 | Chronic myelogenous leukemia | Homo sapiens | |||
Experimental
Result(s) |
Galangin caused a decrease in Bcl-2 levels and markedly increased the apoptotic activity of imatinib both in sensitive or imatinib-resistant Bcr-Abl+ cell lines. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Adenosine A2a receptor (ADORA2A) | Molecule Info | [5] | |
Adenosine A3 receptor (ADORA3) | Molecule Info | [6] | ||
Cytochrome P450 1B1 (CYP1B1) | Molecule Info | [7] | ||
BioCyc | Superpathway of tryptophan utilization | Click to Show/Hide | ||
2 | Superpathway of melatonin degradation | |||
3 | Melatonin degradation I | |||
KEGG Pathway | Rap1 signaling pathway | Click to Show/Hide | ||
2 | Calcium signaling pathway | |||
3 | cAMP signaling pathway | |||
4 | Neuroactive ligand-receptor interaction | |||
5 | Vascular smooth muscle contraction | |||
6 | Parkinson's disease | |||
7 | Alcoholism | |||
8 | Steroid hormone biosynthesis | |||
9 | Tryptophan metabolism | |||
10 | Metabolism of xenobiotics by cytochrome P450 | |||
11 | Ovarian steroidogenesis | |||
12 | Chemical carcinogenesis | |||
13 | MicroRNAs in cancer | |||
NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
2 | IL4 Signaling Pathway | |||
3 | TGF_beta_Receptor Signaling Pathway | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
Pathway Interaction Database | HIF-2-alpha transcription factor network | Click to Show/Hide | ||
Reactome | NGF-independant TRKA activation | Click to Show/Hide | ||
2 | Adenosine P1 receptors | |||
3 | G alpha (s) signalling events | |||
4 | Surfactant metabolism | |||
5 | G alpha (i) signalling events | |||
6 | Endogenous sterols | |||
WikiPathways | Nucleotide GPCRs | Click to Show/Hide | ||
2 | Monoamine Transport | |||
3 | GPCRs, Class A Rhodopsin-like | |||
4 | NGF signalling via TRKA from the plasma membrane | |||
5 | GPCR ligand binding | |||
6 | GPCR downstream signaling | |||
7 | GPCRs, Other | |||
8 | Metapathway biotransformation | |||
9 | Estrogen metabolism | |||
10 | Benzo(a)pyrene metabolism | |||
11 | Tamoxifen metabolism | |||
12 | Tryptophan metabolism | |||
13 | Oxidation by Cytochrome P450 | |||
14 | Nuclear Receptors Meta-Pathway | |||
15 | Estrogen Receptor Pathway | |||
16 | Sulindac Metabolic Pathway | |||
17 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
18 | miR-targeted genes in muscle cell - TarBase | |||
19 | miR-targeted genes in lymphocytes - TarBase | |||
20 | miR-targeted genes in epithelium - TarBase | |||
21 | miR-targeted genes in adipocytes - TarBase | |||
22 | Phase 1 - Functionalization of compounds |